In­dia’s Ci­pla Launch­ing COVID-19 Treat­ment Drug Ci­plenza in Au­gust

Fiji Sun - - ASIA/CHINA NEWS - Philip­pines Pres­i­dent Ro­drigo Duterte Feed­back: fj rosi.doviverata@fi­

In­dia’s phar­ma­ceu­ti­cal com­pany Ci­pla on Fri­day an­nounced it has re­ceived reg­u­la­tory ap­proval from the drug con­troller gen­eral of In­dia (DCGI) for launch­ing Favipi­ravir in the coun­try to be sold un­der the brand name Ci­plenza for re­stricted emer­gency use for the treat­ment of coro­n­avirus pa­tients.

“The ac­cel­er­ated ap­proval for manufactur­ing and mar­ket­ing of the drug is aimed at meet­ing the ur­gent and un­met med­i­cal need for COVID-19 treat­ment op­tions in the coun­try through re­stricted emer­gency use,” the com­pany in a state­ment said.

The com­pany said it will com­mer­cially launch Ci­plenza in the first week of Au­gust and each tablet has been priced less than a dol­lar.

Ci­plenza has been jointly de­vel­oped by Ci­pla and CSIR-In­dian Institute of Chem­i­cal Tech­nol­ogy. In­dia on Fri­day re­ported the num­ber of COVID-19 cases in the coun­try has reached 1,287,945 in­clud­ing 30,601 deaths. Glob­ally In­dia is the third worst COVID-19 -hit coun­try

Newspapers in English

Newspapers from Fiji

© PressReader. All rights reserved.